Compare Jubilant Pharmova with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT PHARMOVA vs AJANTA PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT PHARMOVA AJANTA PHARMA JUBILANT PHARMOVA /
AJANTA PHARMA
 
P/E (TTM) x 13.7 25.6 53.3% View Chart
P/BV x 2.0 6.0 33.2% View Chart
Dividend Yield % 0.8 0.5 184.5%  

Financials

 JUBILANT PHARMOVA    AJANTA PHARMA
EQUITY SHARE DATA
    JUBILANT PHARMOVA
Mar-21
AJANTA PHARMA
Mar-21
JUBILANT PHARMOVA /
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,0471,883 55.6%   
Low Rs2511,258 20.0%   
Sales per share (Unadj.) Rs559.1334.0 167.4%  
Earnings per share (Unadj.) Rs51.875.6 68.5%  
Cash flow per share (Unadj.) Rs80.189.0 90.0%  
Dividends per share (Unadj.) Rs5.009.50 52.6%  
Avg Dividend yield %0.80.6 127.4%  
Book value per share (Unadj.) Rs297.6346.1 86.0%  
Shares outstanding (eoy) m159.2886.53 184.1%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x1.24.7 24.7%   
Avg P/E ratio x12.520.8 60.3%  
P/CF ratio (eoy) x8.117.7 45.9%  
Price / Book Value ratio x2.24.5 48.1%  
Dividend payout %9.712.6 76.8%   
Avg Mkt Cap Rs m103,365135,898 76.1%   
No. of employees `000NANA-   
Total wages/salary Rs m21,7285,483 396.3%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m89,05528,897 308.2%  
Other income Rs m298260 114.8%   
Total revenues Rs m89,35429,157 306.5%   
Gross profit Rs m18,6999,986 187.3%  
Depreciation Rs m4,5161,161 389.0%   
Interest Rs m2,47383 2,990.2%   
Profit before tax Rs m12,0089,002 133.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,7642,463 152.8%   
Profit after tax Rs m8,2446,539 126.1%  
Gross profit margin %21.034.6 60.8%  
Effective tax rate %31.327.4 114.6%   
Net profit margin %9.322.6 40.9%  
BALANCE SHEET DATA
Current assets Rs m29,52522,178 133.1%   
Current liabilities Rs m10,4888,388 125.0%   
Net working cap to sales %21.447.7 44.8%  
Current ratio x2.82.6 106.5%  
Inventory Days Days1353 23.7%  
Debtors Days Days349 360.3%  
Net fixed assets Rs m58,10918,912 307.3%   
Share capital Rs m159174 91.5%   
"Free" reserves Rs m47,24829,777 158.7%   
Net worth Rs m47,40729,951 158.3%   
Long term debt Rs m25,64016 160,248.3%   
Total assets Rs m87,63441,090 213.3%  
Interest coverage x5.9109.8 5.3%   
Debt to equity ratio x0.50 101,242.6%  
Sales to assets ratio x1.00.7 144.5%   
Return on assets %12.216.1 75.9%  
Return on equity %17.421.8 79.7%  
Return on capital %19.830.3 65.4%  
Exports to sales %00-   
Imports to sales %10.20-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m9,117NA-   
Fx inflow Rs m11,20718,097 61.9%   
Fx outflow Rs m9,1172,315 393.9%   
Net fx Rs m2,09015,782 13.2%   
CASH FLOW
From Operations Rs m17,8435,763 309.6%  
From Investments Rs m-7,390-2,824 261.7%  
From Financial Activity Rs m-17,094-3,183 537.1%  
Net Cashflow Rs m-7,289-244 2,990.8%  

Share Holding

Indian Promoters % 46.5 70.3 66.1%  
Foreign collaborators % 4.2 0.0 -  
Indian inst/Mut Fund % 24.2 21.2 113.9%  
FIIs % 23.1 8.7 265.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 49.3 29.7 166.3%  
Shareholders   113,776 52,263 217.7%  
Pledged promoter(s) holding % 0.0 13.7 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT PHARMOVA With:   NUTRAPLUS PR  MANGALAM DRUGS  GANGA PHARMACEUTICALS  RELISH PHARMA  LINCOLN PHAR  



Today's Market

Bloodbath on Dalal Street: 6 Reasons Why Sensex Slumped 1,688 Points Today(Closing)

Indian share markets witnessed negative trading activity throughout the day today and ended deep in the red.

Related Views on News

JUBILANT PHARMOVA 2020-21 Annual Report Analysis (Annual Result Update)

Nov 8, 2021 | Updated on Nov 8, 2021

Here's an analysis of the annual report of JUBILANT PHARMOVA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT PHARMOVA . Also includes updates on the valuation of JUBILANT PHARMOVA .

AJANTA PHARMA Announces Quarterly Results (1QFY22); Net Profit Up 17.6% (Quarterly Result Update)

Jul 31, 2021 | Updated on Jul 31, 2021

For the quarter ended June 2021, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 17.6% YoY). Sales on the other hand came in at Rs 7 bn (up 11.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Jul 8, 2021 | Updated on Jul 8, 2021

Here's an analysis of the annual report of AJANTA PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

AJANTA PHARMA Announces Quarterly Results (4QFY21); Net Profit Up 23.3% (Quarterly Result Update)

Jul 8, 2021 | Updated on Jul 8, 2021

For the quarter ended March 2021, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 23.3% YoY). Sales on the other hand came in at Rs 8 bn (up 11.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 64.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 64.2% YoY). Sales on the other hand came in at Rs 7 bn (up 15.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake(Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

How to Hit Rs 100 Crore Wealth in Your Lifetime(Equitymaster Wealth)

Nov 15, 2021

This is how you can achieve the ambitious goal of a net worth of Rs 100 crore.

Don't Sell these Stocks if the Market Falls(Profit Hunter)

Nov 17, 2021

These are the 3 types of stocks that you should not sell in a market crash.

Infosys vs TCS: Which is Better?(Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing.(Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT PHARMOVA SHARE PRICE


Nov 26, 2021 (Close)

TRACK JUBILANT PHARMOVA

  • Track your investment in JUBILANT PHARMOVA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT PHARMOVA

JUBILANT PHARMOVA 8-QTR ANALYSIS

COMPARE JUBILANT PHARMOVA WITH

MARKET STATS